DiaMedica Therapeutics DMAC
NASDAQ DMAC
$6.52 -0.07 (-1.06%)
As of: Sep 10, 2026 · 10:16 AM EDT

DiaMedica Therapeutics (DMAC) Prepaid Assets (2017 - 2026)

DiaMedica Therapeutics' (DMAC) quarterly Prepaid Assets came in at $567000.0 in Q2 2026, down 16.62% on a YoY basis from $680000.0 in Q2 2025, and down 22.44% quarter-over-quarter from $731000.0 in Q1 2026.

Analysis

DiaMedica Therapeutics (DMAC) Prepaid Assets (2017 - 2026) Analysis & Trends

DiaMedica Therapeutics (DMAC) has reported Prepaid Assets for 10 consecutive years, with $567000.0 the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Prepaid Assets fell 16.62% year-over-year to $567000.0; the trailing twelve-month figure through Jun 2026 stood at $567000.0 (down 16.62% YoY), and the FY2025 full-year result was $481000.0, up 111.89% from the prior year.
  • Prepaid Assets eased to $567000.0 in Q2 2026 per DMAC's latest filing, from $731000.0 in the prior quarter.
  • Across five years, Prepaid Assets topped out at $1.1 million in Q3 2023 and bottomed at $227000.0 in Q4 2024.
  • Historically, Prepaid Assets has averaged $569777.8 across 5 years, with a median of $567500.0 in 2024.
  • The sharpest annual moves came in 2023 and 2024: Prepaid Assets surged 245.03% in 2023, then sank 74.8% in 2024.
  • Over 5 years, Prepaid Assets stood at $251000.0 in 2022, then jumped by 63.75% to $411000.0 in 2023, then sank by 44.77% to $227000.0 in 2024, then surged by 111.89% to $481000.0 in 2025, then rose by 17.88% to $567000.0 in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods registered $567000.0, $731000.0, and $481000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 207.47 Bn 193.48 Bn 7.24 Bn
2 Gilead Sciences 178.76 Bn 175.58 Bn 6.22 Bn
3 Vertex Pharmaceuticals 131.52 Bn 123.67 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.91 Bn 73.91 Bn 3.93 Bn
5 Argenx Se 61.10 Bn 55.91 Bn 1.37 Bn
6 Moderna 53.44 Bn 48.30 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.55 Bn 30.24 Bn 992.69 Mn
8 Biogen 31.67 Bn 30.39 Bn 1.96 Bn
9 Roivant Sciences 29.63 Bn 29.63 Bn 1.16 Mn
10 DiaMedica Therapeutics 351.39 Mn 351.39 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 567,000.00
Mar 31, 2026 731,000.00
Dec 31, 2025 481,000.00
Sep 30, 2025 445,000.00
Jun 30, 2025 680,000.00
Mar 31, 2025 649,000.00
Dec 31, 2024 227,000.00
Sep 30, 2024 280,000.00
Jun 30, 2024 568,000.00
Mar 31, 2024 569,000.00
Dec 31, 2023 411,000.00
Sep 30, 2023 1.11 Mn
Jun 30, 2023 675,000.00
Mar 31, 2023 962,000.00
Dec 31, 2022 251,000.00
Sep 30, 2022 322,000.00
Jun 30, 2022 534,000.00
Mar 31, 2022 793,000.00
Dec 31, 2021 197,000.00
Sep 30, 2021 336,000.00